EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention

Se-Eun Kim, Ho-Sung Jeon, Tae-Hwa Go, Jung-Hee Lee, Jun-Won Lee, Young Jin Youn, Byeong-Keuk Kim, Hyung Joon Joo, Do-Sun Lim, Kiyuk Chang, Yongwhi Park, Young Bin Song und 13 weitere

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.3026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Se-Eun Kim und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Sout…. Hauptthemen laut MEDLINE: Blood Platelets, Cytochrome P-450 CYP2C19, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss‐of‐function (LoF) alleles of cytochrome P450 2C19 ( CYP2C19 ), which are prevalent in East Asians, are linked to high platelet reactivity (HPR) phenotype and poor prognosis. We aimed to investigate the incremental predictive value of HPR combined with CYP2C19 genotype in predicting outcomes after drug‐eluting stent (DES) implantation. The patients treated with platelet function and genotype‐related long‐term prognosis in drug‐eluting stent (PTRG‐DES) consortium enrolled a total of 13,160 Korean patients treated with DES who had platelet function test (PFT) or CYP2C19 genotype, of which, 6,717 patients with PFT and genotype together were categorized. HPR was defined as VerifyNow ≥ 252 P2Y12 reaction unit. The primary outcome was the incidence of major adverse cardiac and cerebrovascular event (MACCE) 5 years after treatment. The patients with both HPR and CYP2C19 LoF/LoF had the highest MACCE rates (6.2%) and increased MACCE risk (adjusted hazard ratio: 1.89, 95% confidence interval: 1.20–2.91, P = 0.006) compared with those without both HPR and CYP2C19 LoF/LoF. There was no effect of interaction between HPR and CYP2C19 genotype on the primary outcome ( P = 0.424). Adding combined HPR and CYP2C19 genotype to the conventional model had an incremental influence in predicting MACCE and stent thrombosis. Compared to the model including HPR or CYP2C19 genotype alone, a combination model significantly improved the risk stratification for stent thrombosis but not MACCE. In DES‐treated East Asian patients, the combined evaluation of PFT results and CYP2C19 genotyping might improve risk prediction of ischemic events during clopidogrel treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsCytochrome P-450 CYP2C19Percutaneous Coronary InterventionAgedFemaleHumansMaleMiddle AgedDrug-Eluting StentsEast Asian PeopleGenotypePlatelet Aggregation InhibitorsPlatelet Function TestsRepublic of KoreaTreatment Outcome

Substanzen

CYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, South Korea.
  • Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Biostatistics, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
  • Division of Cardiology, Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea.
  • Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea.

ORCID-Profile: Sung Gyun Ahn

Zitieren

APA

Kim, S. E., Jeon, H. S., Go, T. H., Lee, J. H., Lee, J. W., Youn, Y. J., Kim, B. K., Joo, H. J., Lim, D. S., Chang, K., Park, Y., Song, Y. B., Suh, J. W., Lee, S. Y., Cho, J. R., Her, A. Y., Kim, H. S., Kim, M. H., Shin, E. S., …, & PTRG-DES consortium investigators (2023). High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3026

Vancouver

Kim SE, Jeon HS, Go TH, Lee JH, Lee JW, Youn YJ, et al. High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.3026

BibTeX
@article{Kim2023,
  author = {Kim, Se-Eun and Jeon, Ho-Sung and Go, Tae-Hwa and Lee, Jung-Hee and Lee, Jun-Won and Youn, Young Jin and Kim, Byeong-Keuk and Joo, Hyung Joon and Lim, Do-Sun and Chang, Kiyuk and Park, Yongwhi and Song, Young Bin and Suh, Jung-Won and Lee, Sang Yeob and Cho, Jung Rae and Her, Ae-Young and Kim, Hyo-Soo and Kim, Moo Hyun and Shin, Eun-Seok and Gorog, Diana A and Tantry, Udaya S and Gurbel, Paul A and Jeong, Young-Hoon and Ahn, Sung Gyun and PTRG-DES consortium investigators, PTRG-DES consortium investigators},
  title = {High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.3026}
}
Kostenlos starten →